Lupin Limited has announced an exciting new partnership program to help more companies benefit from PrecisionSphere™, its long-acting injectable (LAI) platform developed by subsidiary Nanomi B.V. PrecisionSphere™ is already making waves in drug delivery, especially after gaining U.S. FDA approval for its first product.
The goal of Lupin’s program is simple: to collaborate with companies that want to extend the lifecycle of their medicines—whether they’re still in development or already on the market—by offering longer-acting formulations.
What makes PrecisionSphere™ special is its ability to tackle common challenges in drug delivery. Traditional LAI technologies often produce inconsistent particle sizes, which can lead to variable results. PrecisionSphere™, however, ensures medicines have uniform particle size, shape, and biological properties, resulting in smoother injections and more reliable drug delivery over time.
For patients, this means fewer injections and a more convenient treatment experience, which can improve adherence and overall outcomes. Healthcare professionals also benefit, as the platform allows precise control over drug dosage at optimal therapeutic levels, ensuring treatments work as intended.